生物制剂时代的重度哮喘：持续挑战
Severe Asthma in the Era of Biologics: Continuous Challenges.
作者信息
Schoini Pinelopi, Bakakos Petros, Loukides Stelios
机构信息
4th Respiratory Department, Athens Chest Hospital Sotiria, 11527 Athens, Greece.
1st Respiratory Medicine Department, Athens Chest Hospital Sotiria, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
出版信息
J Clin Med. 2023 Jun 5;12(11):3857. doi: 10.3390/jcm12113857.
Abstract
Asthma is a heterogenous disease characterized by different phenotypes and endotypes [...].
摘要
哮喘是一种具有不同表型和内型特征的异质性疾病[……]。
相似文献
1
Severe Asthma in the Era of Biologics: Continuous Challenges.生物制剂时代的重度哮喘：持续挑战
J Clin Med. 2023 Jun 5;12(11):3857. doi: 10.3390/jcm12113857.
2
Biological treatments for severe asthma.严重哮喘的生物治疗。
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):379-386. doi: 10.1097/ACI.0000000000000549.
3
Phenotypes and endotypes of adult asthma: Moving toward precision medicine.成人哮喘的表型和内型：迈向精准医学。
J Allergy Clin Immunol. 2019 Jul;144(1):1-12. doi: 10.1016/j.jaci.2019.05.031.
4
Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.关于生物制剂治疗重度难治性2型哮喘的实用临床观点
J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3363-3370. doi: 10.1016/j.jaip.2020.06.048. Epub 2020 Jul 13.
5
Severe T2-high asthma in the biologics era: European experts' opinion.生物制剂时代的重度 T2 高哮喘：欧洲专家意见。
Eur Respir Rev. 2019 Jul 8;28(152). doi: 10.1183/16000617.0054-2019. Print 2019 Jun 30.
6
Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?嗜酸性粒细胞作为重度嗜酸性哮喘的驱动因素：表型还是可塑性？
Int J Mol Sci. 2021 Sep 21;22(18):10150. doi: 10.3390/ijms221810150.
7
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences.生物制剂在重症哮喘中的应用：临床试验结果——相似性与差异。
Expert Opin Biol Ther. 2022 Jul;22(7):855-870. doi: 10.1080/14712598.2022.2091409. Epub 2022 Jun 23.
8
Severe asthma phenotypes and endotypes.严重哮喘表型和内型。
Semin Immunol. 2019 Dec;46:101301. doi: 10.1016/j.smim.2019.101301. Epub 2019 Aug 27.
9
How to compare the efficacy of biologic agents in asthma.如何比较哮喘生物制剂的疗效。
Ann Allergy Asthma Immunol. 2020 Aug;125(2):137-149. doi: 10.1016/j.anai.2020.04.031. Epub 2020 May 5.
10
New perspectives of biological therapy for severe asthma in adults and adolescents.成人和青少年重度哮喘的生物治疗新视角。
Swiss Med Wkly. 2022 May 27;152:w30176. doi: 10.4414/smw.2022.w30176. eCollection 2022 May 23.
本文引用的文献
1
Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes.参与重度哮喘生物制剂临床试验患者的基线特征作为结局潜在预测指标
J Clin Med. 2023 Feb 15;12(4):1546. doi: 10.3390/jcm12041546.
2
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting.倍那珠单抗治疗依赖口服糖皮质激素的重度哮喘的有效性：真实环境下两年治疗的影响
J Clin Med. 2023 Jan 27;12(3):985. doi: 10.3390/jcm12030985.
3
High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study.重度哮喘患者血液嗜酸性粒细胞水平与支气管扩张的定位：一项初步研究。
J Clin Med. 2023 Jan 3;12(1):380. doi: 10.3390/jcm12010380.
4
Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study.白三烯受体拮抗剂疗法能否改善接受生物疗法且并存支气管扩张的重度哮喘患者的病情控制？一项初步研究。
J Clin Med. 2022 Aug 11;11(16):4702. doi: 10.3390/jcm11164702.
5
The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment.奥马珠单抗治疗成人重度过敏性哮喘的长期疗效：持续治疗与强化治疗对比
J Clin Med. 2021 Feb 11;10(4):707. doi: 10.3390/jcm10040707.
6
Severe Eosinophilic Asthma.重度嗜酸性粒细胞性哮喘
J Clin Med. 2019 Sep 2;8(9):1375. doi: 10.3390/jcm8091375.
Zotero 插件